Literature DB >> 3339397

The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group.

J R Wood1, S B Green, W R Shapiro.   

Abstract

The prognostic importance of tumor size was studied in 510 patients with malignant glioma (80% with glioblastoma multiforme) in the Valid Study Group of Study 80-01 of the Brain Tumor Study Group (now the Brain Tumor Cooperative Group [BTCG]). The endpoint was length of survival from randomization, which occurred within 3 weeks of definitive surgery. Following randomization, patients were scheduled to receive radiotherapy (RT) (6,020 cGy) during a 7-week period, along with continuing courses of chemotherapy. Computed tomographic (CT) scan information was available for 124 patients preoperatively, 300 patients postoperatively (preradiation), and 218 patients 9 weeks post-RT (+/- 3 weeks). Tumor size was determined as area (length x width) on the contrast-enhanced scan and survival was compared by log rank statistics. Preoperative tumor area was unrelated to survival (P = .48), but postoperative area was significantly prognostic (P less than .0001); the smaller the residual tumor, the longer the patient lived. Patients with a 75% or greater resection, as determined by measuring the difference between the preoperative and the postoperative scans, tended to have better survival, but the difference was not significant (P = .16). The post-RT area was strongly related to survival (P less than .00001). The percent change in area between the pre- and post-RT scans was also prognostic. Tumor size was of prognostic importance independent of the other known prognostic variables: age, Karnofsky performance score, and whether the tumor was glioblastoma or anaplastic astrocytoma. We conclude that the amount of tumor remaining after surgery is an important baseline variable at the start of RT, and that the tumor size 9 weeks following RT is also prognostic. Surgical resection is most important when it leaves the least amount of residual tumor.

Entities:  

Mesh:

Year:  1988        PMID: 3339397     DOI: 10.1200/JCO.1988.6.2.338

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  59 in total

Review 1.  The role of image-guided technology in the surgical planning and resection of gliomas.

Authors:  G H Barnett
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 2.  Extent of resection as a prognostic variable in the treatment of gliomas.

Authors:  K R Hess
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 3.  Historical development of surgery for glial tumors.

Authors:  M Salcman
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

4.  Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.

Authors:  A Boiardi; A Silvani; A Pozzi; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 5.  Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Authors:  Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

6.  Cancer treatment - objectives and quality of life issues.

Authors:  Farhat Aziz Khan; Shad Salim Akhtar; Muhammad Kamil Sheikh
Journal:  Malays J Med Sci       Date:  2005-01

7.  SEOM guideline for the treatment of malignant glioma.

Authors:  Alfonso Berrocal; Miguel Gil; Óscar Gallego; Carmen Balaña; Pedro Pérez Segura; Jesús García-Mata; Gaspar Reynes
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

8.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

Review 9.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

10.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.